Wilwerding M B, Loprinzi C L, Mailliard J A, O'Fallon J R, Miser A W, van Haelst C, Barton D L, Foley J F, Athmann L M
Creighton University, University of Nebraska Medical Center and Associates, Omaha 68131, USA.
Support Care Cancer. 1995 Mar;3(2):135-8. doi: 10.1007/BF00365854.
Sedation may be a dose-limiting side-effect of opioid therapy in some cancer patients. This study was designed to evaluate further the use of the psychostimulant, methylphenidate, an agent that has been reported to counter-act opioid-induced sedation, in patients with cancer-related pain. Patients receiving a stable dose of an opioid for cancer-related pain were recruited for this randomized, double-blind, crossover clinical trial. In addition to their regular dose of narcotics, they received 5 days of methylphenidate followed by 5 days of placebo, or vice versa. Our data did not definitively demonstrate any statistically significant benefit for methylphenidate, but did suggest that this drug could mildly decrease narcotic-induced drowsiness and could increase night-time sleep. These data, in conjunction with other published data, suggest that methylphenidate can counteract narcotic-induced daytime sedation to a limited degree.
在一些癌症患者中，镇静可能是阿片类药物治疗的剂量限制性副作用。本研究旨在进一步评估精神振奋药哌醋甲酯（据报道该药物可对抗阿片类药物引起的镇静作用）在癌症相关疼痛患者中的应用。本随机、双盲、交叉临床试验招募了接受稳定剂量阿片类药物治疗癌症相关疼痛的患者。除常规剂量的麻醉药品外，他们接受5天的哌醋甲酯治疗，随后接受5天的安慰剂治疗，或反之。我们的数据并未明确显示哌醋甲酯有任何统计学上的显著益处，但确实表明该药物可轻度减轻麻醉药品引起的嗜睡，并可增加夜间睡眠。这些数据与其他已发表的数据表明，哌醋甲酯可在一定程度上对抗麻醉药品引起的日间镇静作用。
